Kither Biotech Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 9

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $20.6M

  • Investors
  • 13

Kither Biotech General Information

Description

Developer of anticancer and anti-inflammation drugs intended for pulmonary diseases with unmet medical needs. The company provides services in drugs that are researched for the treatment of cystic fibrosis, a disease that predominantly affects the lungs, and is in line to create medication for the cure of chronic obstructive pulmonary diseases, allergic asthma, and idiopathic pulmonary fibrosis, enabling patients to have a treatment for their respiratory diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Via Nizza 52
  • 10126 Turin
  • Italy

Kither Biotech Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kither Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 16-Mar-2022 $20.6M 0000 Completed Pre-Clinical Trials
2. Later Stage VC (Series A) 05-Jul-2019 00.000 00.000 0000 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Startup
To view Kither Biotech’s complete valuation and funding history, request access »

Kither Biotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000 00.000000 000.00 000.00 00 000.00 00.000
To view Kither Biotech’s complete cap table history, request access »

Kither Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of anticancer and anti-inflammation drugs intended for pulmonary diseases with unmet medical needs. The compan
Drug Discovery
Turin, Italy
9 As of 2022
0000
00000000000 0000

0000 0

t nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt
0000 000000000
Austin, TX
00 As of 0000
000.00
0000000000 0 000.00

000000

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000 000000000
Marburg, Germany
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kither Biotech Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lung Therapeutics Venture Capital-Backed Austin, TX 00 000.00 0000000000 0 000.00
000000 00000000000 Venture Capital-Backed Marburg, Germany 0 000.00 00000000000 000.00
00000 Formerly VC-backed Umea, Sweden 0 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
000000 Venture Capital-Backed Seattle, WA 00 00000 000000000 00000
You’re viewing 5 of 24 competitors. Get the full list »

Kither Biotech Patents

Kither Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10730921-B2 Pi3kγ inhibitor peptide for treatment of respiratory system diseases Active 24-Dec-2014 00000000000 0
ES-2737227-T3 Novel pi3k gamma inhibitor peptide for the treatment of diseases of the respiratory system Active 24-Dec-2014 00000000000
EP-3236983-B1 Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases Active 24-Dec-2014 00000000000
US-20190367571-A1 Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases Granted 24-Dec-2014 00000000000
US-20180086798-A1 Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases Granted 24-Dec-2014 C07K14/4703
To view Kither Biotech’s complete patent history, request access »

Kither Biotech Executive Team (7)

Name Title Board Seat Contact Info
Vincent Metzler Ph.D Chief Executive Officer and Board Member
Marco Malisani Chief Financial Officer & Board Member
Alberto Bardelli Co-Founder
Gian Tron Co-Founder
Alessandra Ghigo Scientific Co-Founder
You’re viewing 5 of 7 executive team members. Get the full list »

Kither Biotech Board Members (7)

Name Representing Role Since
Heikki Lanckriet Ph.D Self Board Member 000 0000
Laura Iris Ferro Self Chairman 000 0000
Marco Malisani Kither Biotech Chief Financial Officer & Board Member 000 0000
Pietro Puglisi Claris Ventures Board Member 000 0000
Vincent Metzler Ph.D Kither Biotech Chief Executive Officer and Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Kither Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kither Biotech Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
2invest Corporation Minority 000 0000 000000 0
3B Future Health Ventures Venture Capital Minority 000 0000 000000 0
Ace Ventures Venture Capital Minority 000 0000 000000 0
CDP Venture Capital Venture Capital Minority 000 0000 000000 0
Claris Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »